Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.82+0.08 (+0.21%)
At close: 04:00PM EDT
40.76 +1.94 (+5.00%)
After hours: 07:36PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close38.74
Open38.37
Bid38.75 x 900
Ask38.83 x 1000
Day's Range38.03 - 38.88
52 Week Range31.36 - 52.98
Volume881,733
Avg. Volume1,396,179
Market Cap5.407B
Beta (5Y Monthly)1.24
PE Ratio (TTM)15.40
EPS (TTM)2.52
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
72% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for HALO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Halozyme Therapeutics, Inc.
    HALO: Lowering target price to $51.00HALOZYME THERAPEUTICS INC has an Investment Rating of BUY; a target price of $51.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
Advertisement
Advertisement